Emgality contains the active ingredient galcanezumab-gnlm, which is a monoclonal antibody targeting the CGRP ligand. It is available as a subcutaneous injection in prefilled pens or syringes with doses of 100 mg or 120 mg. Key inactive ingredients include L-histidine, L-histidine hydrochloride monohydrate, Polysorbate 80, and Sodium Chloride.
How should I use this medication?
This medication is injected under the skin. You will be taught how to prepare and give it. Take it as directed on the prescription label. Keep taking it unless your care team tells you to stop. It is important that you put your used needles and syringes in a special sharps container. Do not put them in a trash can. If you do not have a sharps container, call your pharmacist or care team to get one. Talk to your care team about the use of this medication in children. Special care may be needed.
Overdosage: If you think you have taken too much of this medicine contact a poison control center or emergency room at once. NOTE: This medicine is only for you. Do not share this medicine with others.
What if I miss a dose?
If you miss a dose, take it as soon as you can. If it is almost time for your next dose, take only that dose. Do not take double or extra doses.
Where should I keep my medication?
Keep out of the reach of children and pets. Store in a refrigerator or at room temperature between 20 and 25 degrees C (68 and 77 degrees F). Refrigeration (preferred): Store in the refrigerator. Do not freeze. Keep in the original container until you are ready to take it. Remove the dose from the carton about 30 minutes before it is time for you to use it. If the dose is not used, it may be stored in original container at room temperature for 7 days. Get rid of any unused medication after the expiration date. Room Temperature: This medication may be stored at room temperature for up to 7 days. Keep it in the original container. Protect from light until time of use. If it is stored at room temperature, get rid of any unused medication after 7 days or after it expires, whichever is first. To get rid of medications that are no longer needed or have expired: -Take the medication to a medication take-back program. Check with your pharmacy or law enforcement to find a location. -If you cannot return the medication, ask your pharmacist or care team how to get rid of this medication safely.
NOTE: This sheet is a summary. It may not cover all possible information. If you have questions about this medicine, talk to your doctor, pharmacist, or health care provider.
What side effects may I notice from receiving this medication?
Side effects that you should report to your care team as soon as possible: -Allergic reactions or angioedema—skin rash, itching or hives, swelling of the face, eyes, lips, tongue, arms, or legs, trouble swallowing or breathing -Increase in blood pressure -Raynaud syndrome—cool, numb, or painful fingers or toes that may change color from pale, to blue, to red Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome): -Pain, redness, or irritation at injection site
This list may not describe all possible side effects. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What should I tell my care team before I take this medication?
They need to know if you have any of these conditions: -Circulation problems in fingers or toes (Raynaud syndrome) -High blood pressure -An unusual or allergic reaction to galcanezumab, other medications, foods, dyes, or preservatives -Pregnant or trying to get pregnant -Breastfeeding
What may interact with this medication?
Interactions are not expected.
This list may not describe all possible interactions. Give your health care provider a list of all the medicines, herbs, non-prescription drugs, or dietary supplements you use. Also tell them if you smoke, drink alcohol, or use illegal drugs. Some items may interact with your medicine.
What should I watch for while using this medication?
Visit your care team for regular checks on your progress. Tell your care team if your symptoms do not start to get better or if they get worse.
Source: This information is sourced from Elsevier Inc.
The reviews, ratings, comments, and opinions expressed on this platform are solely those of the individual medical professionals who posted them and do not reflect the views or positions of Sermo, Inc. Sermo does not endorse, verify, or validate the content of individual reviews. The information provided is user-generated and reflects personal clinical experiences, which may not be complete, accurate, or applicable to your specific health needs. It is not intended as medical advice.
Prescription medications affect individuals differently, and what works for one person may not work for another. Always consult your doctor, pharmacist, or other qualified healthcare provider to ensure the information displayed applies to your personal circumstances. Only a licensed healthcare provider can advise you on what is safe and effective for you.
Keep all medications out of the reach of children, never share your medicine with others, and use each medication only as prescribed. Your reliance on any information provided on this platform is at your own risk.
Sermo Drug Ratings, and all information provided on this website, may not be used in combination with any artificial intelligence tool (including to train an algorithm, test, process, analyze, generate output and/or develop any form of artificial intelligence tool).
Visitors to the online patient-facing website at Sermo.com (“Sermo Drug Ratings”) are Authorized Users of the website, which contains data owned by a third-party provider, Elsevier, Inc. Accordingly, by visiting Sermo Drug Ratings, Authorized User acknowledges that the website includes Elsevier owned data that Sermo licenses pursuant to a separate usage and Data agreement (the “Agreements”). Authorized User further acknowledges that Sermo is a third-party beneficiary of the Agreements and Authorized User’s use of the website hereby binds them to the terms of the Agreements; provided, however, that Elsevier shall have no obligations or liability to an Authorized User whatsoever pursuant to the terms of the Agreements.